SLC5A2 and type 1 diabetes mellitus: Use of SGLT-2 inhibitors was not abundant in type 1 diabetes and patients receiving them were characterized by a higher mean age (54.6 vs. 44.9 years), higher proportion of males (62.1 vs. 53.6 %), a higher BMI (28.9 vs. 25.8 kg/m2) and a higher prevalence of CVD (25.3 vs. 11.8 %).